Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Substantial Shareholding

19 Jun 2008 17:26

RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
 
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))
 
 
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
 
ReGen Therapeutics Plc
 
2. Reason for the notification:
 
An acquisition or disposal of voting rights
 
3. Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4. Full name of shareholder(s) (if difference from 3):
 
As above
 
5. Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6. Date on which issued notified:
 
19 June 2008
 
7. Threshold(s) that is/are crossed or reached:
 
13%
8. Notified details
 
A: Voting rights attached to shares
 
Class/type of share if possible using the ISIN Code GB00B28XMY25
 
Situation Previous to the triggering transaction (vi) –
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
 
Resulting situation after the triggering transaction (viii) –
Number of Shares 1,495,000
Number of Voting Rights – Direct (x) 1,495,000
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 13.02%
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
 
Type of financial instrument N/A
 
Expiration date (xiii) N/A
 
Exercise/Conversion Period/Date (xiv) N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
 
% of voting rights N/A
Total (A+B)
 
Number of voting rights 1,495,000
 
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10. Name of the proxy holder: N/A
 
11. Number of voting rights proxy holder will cease to hold: N/A
 
12. Date on which proxy holder will cease to hold voting rights: N/A
 
13. Additional information: N/A
 
14. Contact name: N/A
 
15. Contact telephone number: N/A
 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKCKDABKDCAD
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.